Famciclovir: a focus on efficacy and safety

Bibliography

• Aoki FY. Contemporary antiviral drug regimens for the prevention and treatment of orolabial and anogenital herpes simplex virus infection in the normal host: four approved indications and 13 off-label uses. Can J Infect Dis 2003;14(1):17-27
   PubMedGoogle Scholar
• Champness JN, Bennett MS, Wien F, Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands. Proteins 1998;32(3):350-61
   PubMed Web of Science ®Google Scholar
• Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother 1993;4(Suppl 1):47-55
   Google Scholar
• Earnshaw DL, Bacon TH, Darlison SJ, Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992;36(12):2747-57
   PubMed Web of Science ®Google Scholar
• Reardon JE. Herpes simplex virus type 1 and human DNA polymerase interactions with 2′-deoxyguanosine 5′-triphosphate analogues. Kinetics of incorporation into DNA and induction of inhibition. J Biol Chem 1989;264(32):19039-44
   PubMed Web of Science ®Google Scholar
• Reardon JE, Spector T. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem 1989;264(13):7405-11
   PubMed Web of Science ®Google Scholar
• Bacon TH, Howard BA, Spender LC, Boyd MR. Activity of penciclovir in antiviral assays against herpes simplex virus. J Antimicrob Chemother 1996;37(2):303-13
   PubMed Web of Science ®Google Scholar
• Safrin S, Phan L. In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob Agents Chemother 1993;37(10):2241-3
   PubMed Web of Science ®Google Scholar
• Sarisky RT, Bacon TH, Boon RJ, Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Arch Virol 2003;148(9):1757-69
   PubMed Web of Science ®Google Scholar
• Pelosi E, Mulamba GB, Coen DM. Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants. Antiviral Res 1998;37(1):17-28
   PubMed Web of Science ®Google Scholar
• Bae PK, Kim JH, Kim HS, Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1. Antiviral Res 2006;70(3):93-104
   PubMed Web of Science ®Google Scholar
• Bacon TH, Levin MJ, Leary JJ, Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003;16(1):114-28
   PubMed Web of Science ®Google Scholar
• Wild K, Bohner T, Folkers G, Schulz GE. The structures of thymidine kinase from herpes simplex virus type 1 in complex with substrates and a substrate analogue. Protein Sci 1997;6(10):2097-106
   PubMed Web of Science ®Google Scholar
• Sarisky RT, Quail MR, Clark PE, Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J Virol 2001;75(4):1761-9
   PubMed Web of Science ®Google Scholar
• Pardeiro M, Cuenca-Estrella M, Fernandez-Clua MA, Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient. J Med Virol 2004;73(1):60-4
   PubMed Web of Science ®Google Scholar
• Suzutani T, Ishioka K, De Clercq E, Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir. Antimicrob Agents Chemother 2003;47(5):1707-13
   PubMed Web of Science ®Google Scholar
• Pue MA, Pratt SK, Fairless AJ, Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother 1994;33(1):119-27
   PubMed Web of Science ®Google Scholar
• Andrei G, De Clercq E, Snoeck R. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? Antiviral Res 2004;61(3):181-7
   PubMed Web of Science ®Google Scholar
• Boyd MR, Bacon TH, Sutton D. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals. Antimicrob Agents Chemother 1988;32(3):358-63
   PubMed Web of Science ®Google Scholar
• Moomaw MD, Cornea P, Rathbun RC, Wendel KA. Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster. Expert Rev Anti Infect Ther 2003;1(2):283-95
   PubMedGoogle Scholar
• Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antivir Chem Chemother 1993;4:47-55
   Web of Science ®Google Scholar
• Fowles SE, Pierce DM, Prince WT, Staniforth D. The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. Eur J Clin Pharmacol 1992;43(5):513-6
   PubMed Web of Science ®Google Scholar
• Chong DY, Johnson MW, Huynh TH, Vitreous penetration of orally administered famciclovir. Am J Ophthalmol 2009;148(1): 38-42 e1
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Yogev R, Arguedas A, Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. Antimicrob Agents Chemother 2009;53(5):1912-20
   PubMed Web of Science ®Google Scholar
• Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet 1996;31(1):1-8
   PubMed Web of Science ®Google Scholar
• Maru MC, Fialkow RZ, Haria DM. Choreiform movements in dialysis patient taking valacyclovir and famciclovir. South Med J 2001;94(6):655
   PubMed Web of Science ®Google Scholar
• Htwe TH, Bergman S, Koirala J. Famciclovir substitution for patients with acyclovir-associated renal toxicity. J Infect 2008;57(3):266-8
   PubMed Web of Science ®Google Scholar
• Boike SC, Pue M, Audet PR, Pharmacokinetics of famciclovir in subjects with chronic hepatic disease. J Clin Pharmacol 1994;34(12):1199-207
   PubMed Web of Science ®Google Scholar
• Rashidi MR, Smith JA, Clarke SE, Beedham C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 1997;25(7):805-13
   PubMed Web of Science ®Google Scholar
• Baringer JR. Herpes simplex infections of the nervous system. Neurol Clin 2008;26(3):657-74, viii
   PubMed Web of Science ®Google Scholar
• Cunha BA, Eisenstein LE, Dillard T, Krol V. Herpes simplex virus (HSV) pneumonia in a heart transplant: diagnosis and therapy. Heart Lung 2007;36(1):72-8
   PubMed Web of Science ®Google Scholar
• Gooskens J, Templeton KE, Claas EC, Quantitative detection of herpes simplex virus DNA in the lower respiratory tract. J Med Virol 2007;79(5):597-604
   PubMed Web of Science ®Google Scholar
• Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med 2008;168(11):1137-44
   PubMed Web of Science ®Google Scholar
• Chauvin PJ, Ajar AH. Acute herpetic gingivostomatitis in adults: a review of 13 cases, including diagnosis and management. J Can Dent Assoc 2002 68(4):247-51
   PubMedGoogle Scholar
• Spruance SL, Kriesel JD. Treatment of herpes simplex labialis. Herpes 2002;9(3):64-9
   PubMedGoogle Scholar
• Rooney JF, Straus SE, Mannix ML, Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann Intern Med 1993;118(4):268-72
   PubMed Web of Science ®Google Scholar
• Spruance SL, Bodsworth N, Resnick H, Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 2006;55(1):47-53
   PubMed Web of Science ®Google Scholar
• Raborn GW, Grace MG. Recurrent herpes simplex labialis: selected therapeutic options. J Can Dent Assoc 2003 69(8):498-503
   PubMedGoogle Scholar
• Hull C, Spruance S, Tyring S, Hamed K. Single-dose famciclovir for the treatment of herpes labialis. Curr Med Res Opin 2006;22(9):1699-702
   PubMed Web of Science ®Google Scholar
• Bodsworth N, Fife K, Koltun W, Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance. Curr Med Res Opin 2009;25(2):483-7
   PubMed Web of Science ®Google Scholar
• Baker D, Eisen D. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. Cutis 2003;71(3):239-42
   PubMed Web of Science ®Google Scholar
• Alster TS, Nanni CA. Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. Dermatol Surg 1999;25(3):242-6
   PubMed Web of Science ®Google Scholar
• Silverman AK, Laing KF, Swanson NA, Schaberg DR. Activation of herpes simplex following dermabrasion. Report of a patient successfully treated with intravenous acyclovir and brief review of the literature. J Am Acad Dermatol 1985;13(1):103-8
   PubMedGoogle Scholar
• Perkins SW, Sklarew EC. Prevention of facial herpetic infections after chemical peel and dermabrasion: new treatment strategies in the prophylaxis of patients undergoing procedures of the perioral area. Plast Reconstr Surg 1996;98(3):427-33; discussion 34-5
   PubMed Web of Science ®Google Scholar
• Spruance SL, Stewart JC, Freeman DJ, Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis: a multicenter placebo-controlled trial. J Infect Dis 1990;161(2):191-7
   PubMed Web of Science ®Google Scholar
• Spruance SL, Jones TM, Blatter MM, High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003;47(3):1072-80
   PubMed Web of Science ®Google Scholar
• Spruance SL, Hill J. Clinical significance of antiviral therapy for episodic treatment of herpes labialis: exploratory analyses of the combined data from two valaciclovir trials. J Antimicrob Chemother 2004;53(5):703-7
   PubMed Web of Science ®Google Scholar
• Lin L, Chen XS, Cui PG, Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, aciclovir-controlled trial. J Dermatol Treat 2002;13(2):67-72
   PubMed Web of Science ®Google Scholar
• Raborn GW, Martel AY, Lassonde M, Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials. J Am Dent Assoc 2002;133(3):303-9
   PubMed Web of Science ®Google Scholar
• Loveless M, HJ, Sacks SL. Famciclovir in the management of first-episode genital herpes. Infect Dis Clin Prac 1997;6(Suppl 1):S12-S6
   Google Scholar
• Modi S, Van L, Gewirtzman A, Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology. Ther Clin Risk Manag 2008;4(2):409-17
   PubMedGoogle Scholar
• Aoki FY. The continuing evolution of antiviral therapy for recurrent genital herpes: 1-day patient-initiated treatment with famciclovir. Herpes 2007;14(3):62-5
   PubMedGoogle Scholar
• Douglas JM, Critchlow C, Benedetti J, A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984;310(24):1551-6
   PubMed Web of Science ®Google Scholar
• Mindel A, Weller IV, Faherty A, Prophylactic oral acyclovir in recurrent genital herpes. Lancet 1984;2(8394):57-9
   PubMed Web of Science ®Google Scholar
• Gold D, Corey L. Acyclovir prophylaxis for herpes simplex virus infection. Antimicrob Agents Chemother 1987;31(3):361-7
   PubMed Web of Science ®Google Scholar
• Straus SE, Seidlin M, Takiff HE, Double-blind comparison of weekend and daily regimens of oral acyclovir for suppression of recurrent genital herpes. Antiviral Res 1986;6(3):151-9
   PubMed Web of Science ®Google Scholar
• Sacks SL, Fox R, Levendusky P, Chronic suppression for six months compared with intermittent lesional therapy of recurrent genital herpes using oral acyclovir: effects on lesions and nonlesional prodromes. Sex Transm Dis 1988;15(1):58-62
   PubMed Web of Science ®Google Scholar
• Goldberg LH, Kaufman R, Kurtz TO, ; Acyclovir Study Group. Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Arch Dermatol 1993;129(5):582-7
   PubMed Web of Science ®Google Scholar
• Mertz GJ, Eron L, Kaufman R, Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection. Am J Med 1988;85(2A):14-9
   PubMed Web of Science ®Google Scholar
• Diaz-Mitoma F, Sibbald RG, Shafran SD, Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA. 1998;280(10):887-92
   PubMed Web of Science ®Google Scholar
• Wald A, Selke S, Warren T, Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis. 2006;33(9):529-33
   PubMed Web of Science ®Google Scholar
• Bartlett BL, Tyring SK, Fife K, Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol. 2008;43(2):190-5
   PubMed Web of Science ®Google Scholar
• Sacks SL. Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial. J Infect Dis. 2004;189(8):1341-7
   PubMed Web of Science ®Google Scholar
• Leone P, Warren T, Hamed K, Famciclovir reduces viral mucosal shedding in HSV-seropositive persons. Sex Transm Dis. 2007;34(11):900-7
   PubMed Web of Science ®Google Scholar
• Lebrun-Vignes B, Bouzamondo A, Dupuy A, A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol. 2007;57(2):238-46
   PubMed Web of Science ®Google Scholar
• Sacks SL, Aoki FY, Diaz-Mitoma F, ; Canadian Famciclovir Study Group. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. JAMA 1996;276(1):44-9
   PubMed Web of Science ®Google Scholar
• Sacks SL, Aoki FY, Martel AY, Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial. Clin Infect Dis 2005;41(8):1097-104
   PubMed Web of Science ®Google Scholar
• Chosidow O, Drouault Y, Leconte-Veyriac F, Famciclovir vs aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br J Dermatol 2001;144(4):818-24
   PubMed Web of Science ®Google Scholar
• Bodsworth N, Bloch M, McNulty A, 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study. Sex Health 2008;5(3):219-25
   PubMed Web of Science ®Google Scholar
• Aoki FY, Tyring S, Diaz-Mitoma F, Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006;42(1):8-13
   PubMed Web of Science ®Google Scholar
• Abudalu M, Tyring S, Koltun W, Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin Infect Dis 2008;47(5):651-8
   PubMed Web of Science ®Google Scholar
• Vinh DC, Aoki FY. Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective. Expert Opin Pharmacother 2006;7(16):2271-86
   PubMed Web of Science ®Google Scholar
• Romanowski B, Aoki FY, Martel AY, Collaborative Famciclovir HIV Study Group. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. AIDS 2000;14(9):1211-7
   PubMed Web of Science ®Google Scholar
• Schacker T, Hu HL, Koelle DM, Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med 1998;128(1):21-8
   PubMed Web of Science ®Google Scholar
• DeJesus E, Wald A, Warren T, Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188(7):1009-16
   PubMed Web of Science ®Google Scholar
• Gray RH, Wawer MJ, Brookmeyer R, Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357(9263):1149-53
   PubMed Web of Science ®Google Scholar
• Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997;176(3):766-70
   PubMed Web of Science ®Google Scholar
• Delany S, Mlaba N, Clayton T, Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009;23(4):461-9
   PubMed Web of Science ®Google Scholar
• Baeten JM, Strick LB, Lucchetti A, Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008;198(12):1804-8
   PubMed Web of Science ®Google Scholar
• McMahon MA, Siliciano JD, Lai J, The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008;283(46):31289-93
   PubMed Web of Science ®Google Scholar
• Celum C, Wald A, Lingappa JR, Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010;362(5):427-39
   PubMed Web of Science ®Google Scholar
• Gallagher J. Supportive care for viral infections in cancer patients. Curr Opin Oncol 1991;3(4):643-7
   PubMedGoogle Scholar
• Lazarus HM, Belanger R, Candoni A, The Penciclovir Immunocompromised Study Group. Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. Antimicrob Agents Chemother 1999;43(5):1192-7
   PubMed Web of Science ®Google Scholar
• Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant patients. Drugs. 2004;64(24):2763-92
   PubMed Web of Science ®Google Scholar
• Tyring S, Barbarash RA, Nahlik JE, Collaborative Famciclovir Herpes Zoster Study Group. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123(2):89-96
   PubMed Web of Science ®Google Scholar
• Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994;4(4):241-6
   PubMed Web of Science ®Google Scholar
• Shafran SD, Tyring SK, Ashton R, Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004;29(4):248-53
   PubMed Web of Science ®Google Scholar
• Tyring SK, Beutner KR, Tucker BA, Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000;9(9):863-9
   PubMedGoogle Scholar
• Simpson D, Lyseng-Williamson KA. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs 2006;66(18):2397-416
   PubMed Web of Science ®Google Scholar
• Partridge DG, McKendrick MW. The treatment of varicella-zoster virus infection and its complications. Expert Opin Pharmacother 2009;10(5):797-812
   PubMed Web of Science ®Google Scholar
• Li Q, Chen N, Yang J, Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009;(2):CD006866
   Google Scholar
• Tyring S, Belanger R, Bezwoda W, A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001;19(1):13-22
   PubMed Web of Science ®Google Scholar
• Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009;115(1):229-32
   PubMed Web of Science ®Google Scholar
• Lin E, Luscombe C, Wang YY, The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1996;40(2):413-18
   PubMed Web of Science ®Google Scholar
• Lin E, Luscombe C, Colledge D, Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1998;42(8):2132-7
   PubMed Web of Science ®Google Scholar
• Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 1996;24(5):996-1002
   PubMed Web of Science ®Google Scholar
• Main J, Brown JL, Howells C, A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996;3(4):211-5
   PubMed Web of Science ®Google Scholar
• Rayes N, Seehofer D, Bechstein WO, Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation. Clin Transplant 1999;13(6):447-52
   PubMed Web of Science ®Google Scholar
• Berenguer M, Prieto M, Rayon M, Famciclovir treatment in transplant recipients with HBV-related liver disease: disappointing results. Am J Gastroenterol 2001;96(2):526-33
   PubMed Web of Science ®Google Scholar
• Lim SG, Wai CT, Rajnakova A, Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002;51(4):597-9
   PubMed Web of Science ®Google Scholar
• Lai CL, Yuen MF, Hui CK, Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy. J Med Virol 2002;67(3):334-8
   PubMed Web of Science ®Google Scholar
• Trepo C, Jezek P, Atkinson G, Famciclovir in chronic hepatitis B: results of a dose-finding study. J Hepatol 2000;32(6):1011-8
   PubMed Web of Science ®Google Scholar
• de Man RA, Marcellin P, Habal F, A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 2000;32(2):413-7
   PubMed Web of Science ®Google Scholar
• Manns MP, Neuhaus P, Atkinson GF, Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study. Transpl Infect Dis 2001;3(1):16-23
   PubMedGoogle Scholar
• Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994;38(10):2454-7
   PubMed Web of Science ®Google Scholar
• Loveless MS, Stephen L, Harris, John RW. Famciclovir in the management of first-episode genital herpes. Infect Dis Clin Pract 1997;6(Suppl 1):S12-S6
   Google Scholar
• Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore). 1997;76(5):369-80
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Boker KH, Pethig K, Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial. Transplantation 1999;68(10):1503-11
   PubMed Web of Science ®Google Scholar
• Sacks SL, Bishop AM, Fox R, Lee GCY. A double-blind, placebo-controlled trial of the effect of chronically administered oral famciclovir on sperm production in men with recurrent genital herpes infection. Antivir Res 1994;23(Suppl 1):S72
   Google Scholar
• Spruance SL. Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis. J Med Virol 1993;(Suppl 1):27-32
   PubMedGoogle Scholar